罗基纳酶抑制剂与β-阻断剂在初级开角玻璃眼中的有效性和安全性:通过元分析进行系统性审查
Brenda Nana Wandji1,2, Noélie Bacq1, Adèle Ehongo1
1Hôpital Universitaire de Bruxelles (HUB), CUB Hôpital Erasme, Service d'Ophtalmologie, Université Libre de Bruxelles (ULB), Route de Lennik 808, 1070 Bruxelles, Belgium.
Journal of clinical medicine
|March 28, 2024
概括
罗激酶抑制剂 (Rhokis) 在临床上与贝塔抑制剂相比,对于治疗青光眼的治疗没有劣势. 罗基显示出更好的安全概况,系统性副作用较少,支持其市场定位.
科学领域:
- 眼科医生 眼科 眼科
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 青光眼的治疗需要有效和安全的疗法.
- 罗酶抑制剂 (Rhokis) 是一种用于治疗青光眼的新型药物.
- β-阻断剂 (β-βs) 是对玻璃眼的传统标准护理.
研究的目的:
- 为了比较Rhokis与β-βs的有效性和安全性,用于开角玻璃眼.
- 为了支持Rhokis在欧洲的市场定位.
- 进行随机对照试验的系统审查和元分析.
主要方法:
- 三项随机对照试验的系统审查和元分析.
- 搜索了PubMed,EMBASE和Cochrane图书馆的相关研究.
- 评估了偏差风险,并进行了随机效应元分析.
主要成果:
- 贝塔抑制剂在统计学上显示出更好的眼内压力 (IOP) 降低,但这种差异在临床上并不显著.
- 罗基斯主要表现出局部不良影响.
- β抑制剂与主要系统性副作用有关.
结论:
- 在临床上,rho 激酶抑制剂在降低IOP方面与β-抑制剂无差.
- 与β-阻断剂相比,Rhokis具有更高的安全性.
- 这些发现支持使用Rhokis作为对玻璃眼瘤的可行的治疗选择.
相关概念视频
Open Angle Glaucoma: Treatment
440
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
440
Antihypertensive Drugs: Direct Renin Inhibitors
616
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
616
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
424
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
424
Glaucoma: Overview
565
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
565
Angle Closure Glaucoma: Treatment
485
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
485
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
797
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
797


